Pricing updated 2019-03-24. Prices are subject to change without notice.
(–)-Warfarin is a component of (±)-warfarin (Item No. 13566). It is an anticoagulant that interferes with interconversion of vitamin K and vitamin K epoxide and the role of vitamin K in carboxylation of several clotting cascade proteins, inhibiting the initiation of clotting.1 In vivo, (–)-warfarin slows formation of the prothrombin complex and exhibits 6.6-fold more potent anticoagulant activity than (+)-warfarin (Item No. 13526) in rats.2 (–)-Warfarin is primarily metabolized by the cytochrome P450 (CYP) isoform CYP2C9 and genetic polymorphisms in this enyzme, as well as other compounds metabolized by CYP2C9, increase the potential for catastrophic bleeding complications. Formulations containing warfarin have been used to treat and prevent blood clots in atrial fibrillation, heart valve replacement, venous thrombosis, and pulmonary embolism.
Warning - this product is not for human or veterinary use.
View the Cayman Structure Database for chemical structure definitions for many Cayman products
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data pack, and GC-MS data.
1. Hirsh, J., Fuster, V., Ansell, J., et al. American heart association/american college of cardiology foundation guide to warfarin therapy J. Am. Coll. Cardiol. 41(9), 1633-1652 (2003).
2. Breckenridge, A., and Orme, M.L. The plasma half lives and the pharmacological effect of the enantiomers of warfarin in rats Life Sci. II 11(7), 337-345 (1972).